China Biologic Products Holdings Inc (NASDAQ:CBPO) – Investment analysts at Jefferies Financial Group reduced their FY2020 EPS estimates for China Biologic Products in a research report issued to clients and investors on Monday, May 13th. Jefferies Financial Group analyst J. Wong now anticipates that the biopharmaceutical company will earn $3.95 per share for the year, down from their previous estimate of $3.96. Jefferies Financial Group has a “Underperform” rating and a $62.00 price objective on the stock.

Other research analysts have also issued reports about the company. BidaskClub lowered China Biologic Products from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 9th. ValuEngine raised China Biologic Products from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research raised China Biologic Products from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, Credit Suisse Group set a $88.00 target price on China Biologic Products and gave the company a “hold” rating in a research report on Friday, March 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $78.00.

CBPO opened at $94.01 on Wednesday. The firm has a market capitalization of $3.70 billion, a PE ratio of 23.39, a P/E/G ratio of 4.89 and a beta of 1.28. China Biologic Products has a 12 month low of $60.08 and a 12 month high of $107.44.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $129.78 million during the quarter, compared to analyst estimates of $119.50 million. China Biologic Products had a return on equity of 8.81% and a net margin of 27.71%. During the same period in the previous year, the company posted $1.21 EPS.

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc increased its position in China Biologic Products by 11.6% during the 3rd quarter. Vanguard Group Inc now owns 873,552 shares of the biopharmaceutical company’s stock valued at $69,884,000 after buying an additional 90,532 shares in the last quarter. Vanguard Group Inc. increased its position in China Biologic Products by 11.6% during the 3rd quarter. Vanguard Group Inc. now owns 873,552 shares of the biopharmaceutical company’s stock valued at $69,884,000 after buying an additional 90,532 shares in the last quarter. FMR LLC increased its position in China Biologic Products by 64.6% during the 4th quarter. FMR LLC now owns 737,579 shares of the biopharmaceutical company’s stock valued at $55,990,000 after buying an additional 289,485 shares in the last quarter. Maso Capital Partners Ltd increased its position in China Biologic Products by 11.1% during the 4th quarter. Maso Capital Partners Ltd now owns 159,200 shares of the biopharmaceutical company’s stock valued at $12,085,000 after buying an additional 15,900 shares in the last quarter. Finally, Legal & General Group Plc increased its position in China Biologic Products by 25.2% during the 3rd quarter. Legal & General Group Plc now owns 2,357 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 475 shares in the last quarter. 37.31% of the stock is currently owned by institutional investors.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Recommended Story: What is the cash asset ratio?

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.